Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson's disease and its phenotypes
- PMID: 29520900
- DOI: 10.1111/ene.13628
Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson's disease and its phenotypes
Abstract
Background and purpose: Neuromelanin of the brainstem, which is considered a marker of neurodegeneration in Parkinson's disease (PD), can be detected by T1-weighted neuromelanin-sensitive magnetic resonance imaging (NM-MRI). Our aim was to investigate the NM-MRI features of de novo PD and to determine whether these features are associated with motor and non-motor symptoms in de novo PD patients.
Methods: Fifty-one patients with de novo PD (Hoehn and Yahr stage 1-2) and 28 healthy controls were recruited. All subjects underwent clinical and MRI examinations including an NM-MRI sequence. The width and contrast-to-noise ratio (CNR) of the substantia nigra pars compacta (SNc) and the CNR of the locus coeruleus (LC) were measured on NM-MRI images.
Results: Both the width and CNR values of the high intensity signals in the SNc were significantly decreased in the lateral, central and medial SNc parts in de novo PD patients compared to control subjects. The changes in the SNc on NM-MRI were not significantly different between the motor subgroups. The CNR values of the left LC were significantly lower in the PD group than in the control group. Specifically, the subtype of PD patients with depressive symptoms exhibited a significantly lower CNR in the left LC than the control group and PD patients without depressive symptoms.
Conclusions: Substantia nigra pars compacta neuromelanin changes occur across both motor and non-motor (with and without depressive symptoms) subtypes, whilst LC changes are more notable in PD patients with depressive symptoms. Our results may provide new evidence to understand the pathophysiology of non-motor symptoms in PD.
Keywords: MRI; Parkinson's disease; depressive symptoms; neuromelanin; subtype.
© 2018 EAN.
Similar articles
-
Neuromelanin-sensitive MRI of the substantia nigra: An imaging biomarker to differentiate essential tremor from tremor-dominant Parkinson's disease.Parkinsonism Relat Disord. 2019 Jan;58:3-8. doi: 10.1016/j.parkreldis.2018.07.007. Epub 2018 Jul 17. Parkinsonism Relat Disord. 2019. PMID: 30037690
-
Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients.Eur J Neurol. 2015 Mar;22(3):540-6. doi: 10.1111/ene.12613. Epub 2014 Dec 22. Eur J Neurol. 2015. PMID: 25534480
-
An investigation of neuromelanin distribution in substantia nigra and locus coeruleus in patients with Parkinson's disease using neuromelanin-sensitive MRI.BMC Neurol. 2023 Aug 14;23(1):301. doi: 10.1186/s12883-023-03350-z. BMC Neurol. 2023. PMID: 37580712 Free PMC article.
-
Neuromelanin-sensitive magnetic resonance imaging: Possibilities and promises as an imaging biomarker for Parkinson's disease.Eur J Neurosci. 2024 May;59(10):2616-2627. doi: 10.1111/ejn.16296. Epub 2024 Mar 5. Eur J Neurosci. 2024. PMID: 38441250 Review.
-
Neuromelanin in parkinsonian disorders: an update.Int J Neurosci. 2017 Dec;127(12):1116-1123. doi: 10.1080/00207454.2017.1325883. Epub 2017 May 11. Int J Neurosci. 2017. PMID: 28460588 Review.
Cited by
-
NigraNet: An automatic framework to assess nigral neuromelanin content in early Parkinson's disease using convolutional neural network.Neuroimage Clin. 2022;36:103250. doi: 10.1016/j.nicl.2022.103250. Epub 2022 Oct 31. Neuroimage Clin. 2022. PMID: 36451356 Free PMC article.
-
The Noradrenergic System in Parkinson's Disease.Front Pharmacol. 2020 Apr 8;11:435. doi: 10.3389/fphar.2020.00435. eCollection 2020. Front Pharmacol. 2020. PMID: 32322208 Free PMC article. Review.
-
Locus Coeruleus Shows a Spatial Pattern of Structural Disintegration in Parkinson's Disease.Mov Disord. 2022 Mar;37(3):479-489. doi: 10.1002/mds.28945. Epub 2022 Feb 3. Mov Disord. 2022. PMID: 35114035 Free PMC article.
-
Quantitative iron-neuromelanin MRI associates with motor severity in Parkinson's disease and matches radiological disease classification.Front Aging Neurosci. 2023 Nov 27;15:1287917. doi: 10.3389/fnagi.2023.1287917. eCollection 2023. Front Aging Neurosci. 2023. PMID: 38090717 Free PMC article.
-
Neuromelanin-sensitive MRI for mechanistic research and biomarker development in psychiatry.Neuropsychopharmacology. 2024 Nov;50(1):137-152. doi: 10.1038/s41386-024-01934-y. Epub 2024 Aug 19. Neuropsychopharmacology. 2024. PMID: 39160355 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous